All Publications

  • Therapeutic Plasma Exchange After Spontaneous Intracranial Hemorrhage for a Patient With Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia. Journal of clinical apheresis Nicholas, J., Wali, J., Ellis-Caleo, T., Virk, M. S., Yunce, M. 2025; 40 (5): e70064

    Abstract

    Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL), macro- and micro-vascular thromboembolic complications. Lupus anticoagulant-hypoprothrombinemia (LAHPS) may confound the diagnosis and management of bleeding. Catastrophic APS has a category 1 indication for therapeutic plasma exchange (TPE). However, in patients with APS, LAHPS, and intracranial hemorrhage (ICH), TPE is not well described. A 47-year-old man with known APS anticoagulated on warfarin was transferred for diffuse spontaneous subdural hemorrhages (SDH) with somnolence. aPL levels were elevated on presentation; anti-β2-glycoprotein-I antibody (aβ2GPI) IgG was higher than the reportable range. Factor II activity level was 20% despite holding warfarin: concerning for LAHPS. TPE was initiated to minimize risk of thromboembolism while holding anticoagulation. Level of consciousness improved by the second TPE. An acute lacunar infarct was detected on MRI, but this may have occurred before initiating TPE. Measures of lupus anticoagulant and anticardiolipin (aCL) IgG decreased initially, but aβ2GPI IgG remained above the reportable range. Both aCL and aβ2GPI IgM titers increased initially but decreased by day 31. Factor II activity level improved but remained below normal. Serial imaging showed resolution of SDH without new infarction. In patients with APS and recurrent thromboembolic disease, assessment and treatment of ICH may be confounded by LAHPS. Reversal of anticoagulation is reserved for patients in extremis, and treatment of LAHPS has previously been associated with thrombosis. In this context, TPE may be considered in combination with steroids and rituximab to bridge overlapping thromboembolic and hemorrhagic risk.

    View details for DOI 10.1002/jca.70064

    View details for PubMedID 41116301

  • Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nature communications Nassar, A. H., Kim, C., Adeyelu, T., Bou Farhat, E., Abushukair, H., Rakaee, M., Matteson, K., Lau, S., Takabe, Y., Ocejo, A., Ardeshir-Larijani, F., Leal, T., Ramalingam, S., Alam, S., Gray, J. E., Hicks, J., Kaldas, D., Baena, J., Berjaga, M. Z., Nana, F. A., Grohe, C., Leuders, H., Citarella, F., Cortellini, A., Mingo, E. C., Pancirer, D., Das, M., Ellis-Caleo, T. J., Cheung, J. M., Lin, J. J., Watson, A. S., Camidge, D. R., Sridhar, A., Parikh, K., Crowley, F., Marron, T. U., Aggarwal, V., Ahmed, M., Sankar, K., Kawtharany, H., Zhang, J., Owen, D. H., Li, M., Nagasaka, M., Pinato, D. J., Awosika, N., Alhamad, K., Puri, S., Zaman, U., Gupta, D. M., Lau, C., Khan, H., Liauw, J., Velazquez, A. I., Brown, T., Moliner, L., Mosteiro, M., Rocha, P., Evans, M., Vanderwalde, A., Elliott, A., Nieva, J., Lopes, G., Ma, P. C., Borghaei, H., Lee, M., Young, L., Aljumaily, R., Mirza, H., Kwiatkowski, D. J., Herbst, R. S., Flavell, R. A., Naqash, A. R., Chiang, A. C. 2025; 16 (1): 7717

    Abstract

    Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observe comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events. Genomic analysis identifies distinct non-small cell lung cancer-like (NSCLC-like, KEAP1, KRAS, STK11 mutations) and SCLC-like (RB1, TP53 mutations) LCNEC subtypes, with 80% aligning with SCLC transcriptional profiles. Serial sampling reveals stable mutational but shifting transcriptomic landscapes over time. Here we show, elevated FGL-1 (a LAG-3 ligand) and SPINK1 expression in NSCLC-like LCNECs, and higher levels of DLL3 in SCLC-like LCNECs. Immunofluorescence confirms FGL-1 expression in NSCLC-like LCNECs, and H&E slide analyses indicates fewer tumor-infiltrating lymphocytes in LCNECs versus other lung cancers. These findings highlight LCNEC's distinct immunogenomic profile, supporting future investigations into LAG-3, SPINK1, and DLL3-targeted therapies.

    View details for DOI 10.1038/s41467-025-63091-0

    View details for PubMedID 40830141

  • Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study CLINICAL LUNG CANCER Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., Kurian, A. W., Han, S. S. 2024; 25 (8)

    View details for DOI 10.1016/j.clc.2024.08.017

    View details for Web of Science ID 001364673600001

  • Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study. Clinical lung cancer Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., Kurian, A. W., Han, S. S. 2024

    Abstract

    Long-term breast cancer (BC) survivors are known to develop second malignancies, with second primary lung cancer (SPLC) one common type. Smoking was identified as a main risk factor for SPLC among BC survivors. These findings were limited to the U.S. and focused on smoking status, not incorporating cumulative smoking exposures (eg, pack-years). We examine SPLC incidence and evaluate the associations between SPLC risk and cumulative cigarette smoking exposures and other potential factors among BC survivors in a prospective European cohort.Of 502,505 participants enrolled in the UK Biobank in 2006 to 2010, we identified 8429 patients diagnosed with BC between 2006 and 2016 and followed for second malignancies through 2016. Smoking information was collected at enrollment, and treatment data were collected using electronic health records. Multivariable cause-specific Cox regression (CSC) evaluated the association between each factor and SPLC risk.Of 8429 BC patients, 40 (0.47%) developed SPLC over 45,376 person-years. The 10-year cumulative SPLC incidence was 0.48% (95% CI = 0.33%-0.62%). The CSC analysis confirmed the association between SPLC and ever-smoking status (adjusted hazard-ratio (aHR) = 3.46 (P < .001). The analysis showed a 24% increment in SPLC risk per 10 smoking pack-years among BC survivors (aHR = 1.24 per-10 pack-years, P = .01). The associations between SPLC and other variables remained statistically insignificant. We applied the USPSTF lung cancer screening eligibility criteria and found that 80% of the 40 BC survivors who developed SPLC would have been ineligible for lung cancer screening.In a large, European cohort, cumulative smoking exposure is significantly associated with SPLC risk among BC survivors.

    View details for DOI 10.1016/j.cllc.2024.08.017

    View details for PubMedID 39332922

  • Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study Matteson, K., Nassar, A., Ellis-Caleo, T., Mingo, E. C., Aggarwal, V., Sridhar, A., Alam, S., Crowley, F., Nana, F., Ahmed, M., Grohe, C., Berjaga, M., Pinato, D., Watson, A. S., Chiang, A. C., Naqash, A. LIPPINCOTT WILLIAMS & WILKINS. 2024

    View details for Web of Science ID 001275557402098

  • Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy. Nature cancer Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradic, M., Torres, I. A., Oladipo, E., New, C., Kenney, D. E., Avedian, R. S., Steffner, R. J., Binkley, M. S., Mohler, D. G., Tap, W. D., D'Angelo, S. P., van de Rijn, M., Ganjoo, K. N., Bui, N. Q., Charville, G. W., Newman, A. M., Moding, E. J. 2024

    Abstract

    Characterization of the diverse malignant and stromal cell states that make up soft tissue sarcomas and their correlation with patient outcomes has proven difficult using fixed clinical specimens. Here, we employed EcoTyper, a machine-learning framework, to identify the fundamental cell states and cellular ecosystems that make up sarcomas on a large scale using bulk transcriptomes with clinical annotations. We identified and validated 23 sarcoma-specific, transcriptionally defined cell states, many of which were highly prognostic of patient outcomes across independent datasets. We discovered three conserved cellular communities or ecotypes associated with underlying genomic alterations and distinct clinical outcomes. We show that one ecotype defined by tumor-associated macrophages and epithelial-like malignant cells predicts response to immune-checkpoint inhibition but not chemotherapy and validate our findings in an independent cohort. Our results may enable identification of patients with soft tissue sarcomas who could benefit from immunotherapy and help develop new therapeutic strategies.

    View details for DOI 10.1038/s43018-024-00743-y

    View details for PubMedID 38429415

    View details for PubMedCentralID 4486342

  • Patient-reported outcome measurement implementation in cancer survivors: a systematic review. Journal of cancer survivorship : research and practice Singhal, S., Dickerson, J., Glover, M. J., Roy, M., Chiu, M., Ellis-Caleo, T., Hui, G., Tamayo, C., Loecher, N., Wong, H. N., Heathcote, L. C., Schapira, L. 2022

    Abstract

    Patient-reported outcome measurements (PROMs) are increasingly used for cancer patients receiving active treatment, but little is known about the implementation and usefulness of PROMs in cancer survivorship care. This systematic review evaluates how cancer survivors and healthcare providers (HCPs) perceive PROM implementation in survivorship care, and how PROM implementation impacts cancer survivors' health outcomes.We systematically searched PubMed/MEDLINE, Embase, CINAHL, Web of Science, and Cochrane Database of Systematic Reviews from database inception to February 2022 to identify randomized and nonrandomized studies of PROM implementation in cancer survivors.Based on prespecified eligibility criteria, we included 29 studies that reported on 26 unique PROMs. The studies were heterogeneous in study design, PROM instrument, patient demographics, and outcomes. Several studies found that cancer survivors and HCPs had favorable impressions of the utility of PROMs, and a few studies demonstrated that PROM implementation led to improvements in patient quality of life (QoL), with small to moderate effect sizes.We found implementation of PROMs in cancer survivorship care improved health outcomes for select patient populations. Future research is needed to assess the real-world utility of PROM integration into clinical workflows and the impact of PROMs on measurable health outcomes.Cancer survivors accepted PROMs. When successfully implemented, PROMs can improve health outcomes after completion of active treatment. We identify multiple avenues to strengthen PROM implementation to support cancer survivors.

    View details for DOI 10.1007/s11764-022-01216-w

    View details for PubMedID 35599269

  • The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. Journal of thoracic disease Ellis-Caleo, T., Neal, J. W. 2021; 13 (8): 4864-4871

    Abstract

    Ramucirumab paired with docetaxel extends progression free survival and overall survival in non-small cell lung cancer (NSCLC) following progression on platinum therapy. There is some data that epidermal growth factor receptor (EGFR) mutant disease would respond better to vascular endothelial growth factor receptor (VEGFR) therapy than EGFR wild type disease.This retrospective, single-institution cohort study reports outcomes of patients who received docetaxel with or without ramucirumab according to EGFR status. Clinical data including age, performance status, metastatic burden and prior treatment history was obtained and reported with time on treatment and overall survival as primary endpoints. Data analysis was performed for three cohorts: EGFR mutant disease receiving docetaxel and ramucirumab (EGFR-doce/ram), EGFR mutant disease receiving docetaxel alone (EGFR-doce) and EGFR wild type disease receiving docetaxel and ramucirumab (WT-doce/ram).Patients in the EGFR-doce/ram cohort had a median time on docetaxel of 1.4 months (95% CI: 0.72-5.2 months) and of 0.8 months (95% CI: 0.2-6.5 months) on ramucirumab. Patients in the EGFR-doce cohort were on docetaxel for a median 1.4 months (95% CI: 0.9-2.4 months). Patients in the WT-doce/ram cohort had a median time on docetaxel of 2.3 months (95% CI: 1.6-4.1 months) and on ramucirumab of 1.4 months (95% CI: 0.8-3.2 months). There was no significant difference between time on ramucirumab or docetaxel between the cohorts. Overall survival for the three cohorts was noted to be 6.7 months (95% CI: 2.5-16.2 months) for the EGFR-doce/ram cohort, 4.9 months (95% CI: 4.2-12.5 months) for the EGFR-doce cohort and 6.6 months (95% CI: 4.3-12.8 months) for the WT-doce/ram cohort. There was no significant difference in overall survival between the cohorts.Our data did not support the initial hypothesis that patients with EGFR mutant disease would do better with the addition of ramucirumab. Our study was limited by small sample size, retrospective nature and inability to control for confounders including prior bevacizumab or immune checkpoint inhibitor (ICI) exposure. This study offers real-world estimates to clinicians and patients about the length of time they can expect to derive benefit from the combination of ramucirumab and docetaxel.

    View details for DOI 10.21037/jtd-21-557

    View details for PubMedID 34527325

    View details for PubMedCentralID PMC8411152

  • A SURPRISING CAUSE OF SUB-ACUTE ABDOMINAL SYMPTOMS DURING THE COVID PANDEMIC Ellis-Caleo, T. J., Yecies, E. B. SPRINGER. 2021: S372-S373

    View details for Web of Science ID 000679443300931

  • High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. Journal of thoracic disease Ellis-Caleo, T., Lisberg, A., Tucker, D. A., Garon, E. B. 2018; 10 (Suppl 3): S397-S403

    Abstract

    Traditionally, study results have been presented as abstracts at major scientific meetings at the conclusion of the analysis. Recently, presentations of studies in progress and updates to previously presented data have been allowed at major meetings. The frequency and implications of a single study being presented multiple times, particularly in high profile oral presentations, have not been fully evaluated.To identify studies presented multiple times, abstracts from an approximately 1-year period from international conferences for three major societies devoted largely or in part to lung cancer research were assessed (ASCO 2015, World Lung 2015, ESMO 2015 and ASCO 2016). Abstracts were selected in a two-step process. The first step was for subject matter based on keywords: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) or immunotherapy. Searches differed slightly based on individual website functionality, with ASCO searched by track, World Lung by session and ESMO by individual abstract. In a second step, abstracts for which clinical outcome data was presented from a trial with an identifiable National Clinical Trial (NCT) number were selected. Immunotherapy abstracts that did not include the treatment of NSCLC or SCLC were excluded in the second step.A total of 851 abstracts were identified that were related to NSCLC, SCLC or immunotherapy. Of these, 357 referred to a clinical trial. In total, 110 of 357 (31%) described clinical trials that were presented multiple times (mean 2.75, range 2-7), and in 44 (12%), this occurred at the same conference. Of the 113 oral presentations, 75 (66%) presented data from clinical trials, either as posters or oral presentations. Further, 35 of the 113 (31%) oral presentations presented data from clinical trials that had generated other oral presentations. Of the 16 unique clinical trials leading to multiple oral presentations, a variety of issues led to the duplicate presentations, including different cohorts of the same trial, biomarker analysis, analysis by one study variable, or simply updated data. Moreover, 107 of the 357 (30%) clinical trial abstracts pertained to immunotherapy, including 4 of the 16 clinical trials generating multiple oral presentations. Of the 16 trials generating multiple oral presentations, 11 (69%) lead to a full-length publication by July 2017, including all of those pertaining to immunotherapy.There is a pattern of multiple presentations of clinical trials, particularly in oral presentations, at major meetings. In most cases, data presented in subsequent oral presentations related entirely to patients whose data was presented in the previous oral presentation.

    View details for DOI 10.21037/jtd.2018.01.110

    View details for PubMedID 29593885

    View details for PubMedCentralID PMC5861271

  • Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. Anticancer research Ellis-Caleo, T., Hegde, J. V., Batth, S., Mesko, S., Reiter, R., Margolis, D., Kamrava, M. 2017; 37 (3): 1237-1242

    Abstract

    We evaluated whether sub-stratifying intermediate-risk (IR) prostate cancer using the Memorial Sloan Kettering Cancer (MSKCC) or Prostate Cancer Risk Stratification (ProCaRS) model predicts for adverse imaging or pathologic features.56 consecutive IR patients who underwent multi-parametric MRI (mpMRI) and radical prostatectomy (RP) were studied. The different groups were tested for correlation with adverse findings. 2-sample T-tests assuming unequal variance were used.On mpMRI the MSKCC unfavorable group had higher index lesion suspicion scores (p=0.044), while the ProCaRS model showed a higher maximum tumor diameter (MTD) in the high-risk group (p=0.047). At RP, a higher pathologic MTD (23.3 vs. 17.6 mm, p=0.005) was present in the MSKCC unfavorable group as well as the ProCaRS high vs. low group (26.6 vs. 19.3 mm, p=0.022).Both models demonstrated a correlation with higher MTD for unfavorable IR patients. This is likely a driver of worse clinical outcomes.

    View details for DOI 10.21873/anticanres.11439

    View details for PubMedID 28314287

  • Density Functional Theory of MH-MOH Solid Solubility (M = Alkali) and Experiments in NaH-NaOH JOURNAL OF PHYSICAL CHEMISTRY C Wang, G., Carr, C. L., Zhao, D., Sorte, E. G., Ellis-Caleo, T., Conradi, M. S., Bowman, R. C., Majzoub, E. H. 2015; 119 (15): 8062-8069

    View details for DOI 10.1021/acs.jpcc.5b01134

    View details for Web of Science ID 000353249500011

  • NMR Study of Anion Dynamics in Solid KAlH<sub>4</sub> JOURNAL OF PHYSICAL CHEMISTRY C Sorte, E. G., Emery, S. B., Majzoub, E. H., Ellis-Caleo, T., Ma, Z. L., Hammann, B. A., Hayes, S. E., Bowman, R. C., Conradi, M. S. 2014; 118 (11): 5725-5732

    View details for DOI 10.1021/jp5001978

    View details for Web of Science ID 000333381300013

  • Effects of NaOH in Solid NaH: Solution/Segregation Phase Transition and Diffusion Acceleration JOURNAL OF PHYSICAL CHEMISTRY C Sorte, E. G., Majzoub, E. H., Ellis-Caleo, T., Hammann, B. A., Wang, G., Zhao, D., Bowman, R. C., Conradi, M. S. 2013; 117 (45): 23575-23581

    View details for DOI 10.1021/jp4093892

    View details for Web of Science ID 000327110500017